Cannex Scientific Announces Agreement to Advance Commercialization of FDA-Regulated Cannabinoid Therapies

4.6 min readPublished On: June 29th, 2021By

PITTSBURGH–Cannex Scientific Inc. a biopharmaceutical company focused on therapeutic discoveries in the area of cannabinoid medicine, today announced it has entered into a sponsored research agreement with Brigham and Women’s Hospital. Cannex Scientific, through this collaboration, is implementing a novel drug discovery platform to advance cannabinoid therapies in multiple unmet health needs. This model positions Cannex Scientific to identify nature identical compound combinations that exhibit superior therapeutic benefits. These natural compounds have a record of safe human intake resulting increased likelihood of rapid progression to IND, successful clinical testing, and attainment of FDA approval.

Cannex Scientific is applying its novel biopharmaceutical drug discovery platform to address unmet medical needs in neurobiology, gastroesophageal disorders, and lung injury induced by respiratory viruses. Initial work has led to the identification of a compound pair that has demonstrated significant in vitro activity in one of these therapeutic areas.

The research will be led by Dr. Aaron Goldman an Instructor in Medicine at Harvard Medical School and Associate Bioengineer in the Division of Engineering in Medicine at the Brigham who has a wide range of expertise in the discovery and translation of therapeutics and clinical platforms from the bench to industry, Dr. Luke P. Lee, a Professor of Medicine at Harvard Medical School and global-leading pioneer in pre-clinical bioengineering tools, and Dr. Ilana Braun Physician in the Department of Psychiatry at the Brigham and an Assistant Professor at Harvard Medical School. The team brings together a confluence of expertise in clinical medicine, human physiological models and microfluidic tools that allow for multiplex screening of cannabinoids and terpenes in numerous diseases and indications.

Rebecca Bagley, President and Chief Executive Officer of Cannex Scientific said: “We are excited to work with Dr. Goldman and the research team to develop rigorous science-based discoveries in the endocannabinoid system that leverages the therapeutic potential of nature identical cannabinoids, a goal that has not been realized to-date in the marketplace. These discoveries position us to develop therapies with natural compounds that have a record of safe human intake providing a potential rapid path to IND through clinical testing, FDA approval and entry into the pharmaceutical market,” Bagley continued.

Dr. Bork Balkan, Chief Scientific Officer of Cannex Scientific says: “The drug discovery paradigm that Cannex Scientific employs positions us to harness the therapeutic benefits of plant extracts that are often the result of the combination of more than one compound, affecting more than one biological pathway. Our collaboration with the research team enables us to exploit state-of-the-art microfluidic organoid systems that provide a more physiological in vitro organ model than single cell type in vitro screens that are traditionally used for drug screening. This collaboration will also give us access to sophisticated in vivo models to demonstrate the efficacy of our compounds.”

The research team will focus on a number of biological and bioengineering platforms including an animal model of neuropsychiatric conditions such as anxiety and social phobia that the Goldman-Braun team published in Nature Translational Psychiatry.  In addition, the team will deploy biological platforms that mimic the natural physiology of the human brain and lung microenvironments.

Dr. Goldman stated, “This collaboration with Cannex Scientific is designed to robustly test and discover the power of the entourage effect in pre-clinical models.  We are excited about the potential for new therapeutic discoveries that can be quickly translated to help patients.”

Forward-Looking Statements

This news release includes forward-looking information and statements, which may include, but ‎are not limited to, information and statements regarding or inferring the future business, ‎operations, financial performance, prospects, and other plans, intentions, expectations, estimates, ‎and beliefs of the Company. Words such as “expects”, ‎‎”continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify ‎forward-looking statements. These forward-looking statements are based on the Company’s ‎current projections and expectations about future events and financial trends that management ‎believes might affect its financial condition, results of operations, business strategy and financial ‎needs, and on certain assumptions and analysis made by the Company in light of the experience ‎and perception of historical trends, current conditions and expected future developments and ‎other factors management believes are appropriate. Forward-looking information and statements ‎involve and are subject to assumptions and known and unknown risks, uncertainties, and other ‎factors which may cause actual events, results, performance, or achievements of the Company ‎to be materially different from future events, results, performance, and achievements expressed ‎or implied by forward-looking information and statements herein. Although the Company ‎believes that any forward-looking information and statements herein are reasonable, in light of ‎the use of assumptions and the significant risks and uncertainties inherent in such information ‎and statements, there can be no assurance that any such forward-looking information and ‎statements will prove to be accurate, and accordingly readers are advised to rely on their own ‎evaluation of such risks and uncertainties and should not place undue reliance upon such ‎forward-looking information and statements. Any forward-looking information and statements ‎herein are made as of the date hereof, and except as required by applicable laws, the Company ‎assumes no obligation and disclaims any intention to update or revise any forward-looking ‎information and statements herein or to update the reasons that actual events or results could or ‎do differ from those projected in any forward looking information and statements herein, whether ‎as a result of new information, future events or results, or otherwise, except as required by ‎applicable laws.‎

(This information is primarily sourced from Cannex Scientific.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News

  • Financial Result, CBD Skin Care Market, Cannabis Testing Market

Global Cannabis Testing Market Analysis Report 2023-2030

February 4th, 2023|

DUBLIN - Global Cannabis Testing Market to Reach $2.8 Billion by 2030 In the changed post COVID-19 business landscape, the global market for Cannabis Testing estimated at US$1.1 Billion in the year 2022, is projected to reach ...